<- Go Home
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Market Cap
$5.7B
Volume
1.1M
Cash and Equivalents
$348.9M
EBITDA
-$354.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$147.7M
Profit Margin
-19.02%
52 Week High
$54.44
52 Week Low
$35.95
Dividend
N/A
Price / Book Value
19.07
Price / Earnings
-14.50
Price / Tangible Book Value
19.07
Enterprise Value
$5.4B
Enterprise Value / EBITDA
-16.75
Operating Income
-$367.4M
Return on Equity
-98.27%
Return on Assets
-8.13
Cash and Short Term Investments
$2.2B
Debt
$2.0B
Equity
$296.5M
Revenue
$776.6M
Unlevered FCF
-$109.2M
Sector
Biotechnology
Category
N/A